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Background. Most traditional Chinese herbal formulas consist of at least four herbs. Four-Agents-Decoction (Si Wu Tang) is
a documented eight hundred year old formula containing four herbs and has been widely used to relieve menstrual discomfort
in Taiwan. However, no specific effect had been systematically evaluated. We applied Western methodology to assess its
effectiveness and safety for primary dysmenorrhoea and to evaluate the compliance and feasibility for a future trial.
Methodology/Principal Findings. A randomised, double-blind, placebo-controlled, pilot clinical trial was conducted in an ad
hoc clinic setting at a teaching hospital in Taipei, Taiwan. Seventy-eight primary dysmenorrheic young women were enrolled
after 326 women with self-reported menstrual discomfort in the Taipei metropolitan area of Taiwan were screened by
a questionnaire and subsequently diagnosed by two gynaecologists concurrently with pelvic ultrasonography. A dosage of 15
odorless capsules daily for five days starting from the onset of bleeding or pain was administered. Participants were followed
with two to four cycles for an initial washout interval, one to two baseline cycles, three to four treatment cycles, and three
follow-up cycles. Study outcome was pain intensity measured by using unmarked horizontal visual analog pain scale in an
online daily diary submitted directly by the participants for 5 days starting from the onset of bleeding or pain of each
menstrual cycle. Overall-pain was the average pain intensity among days in pain and peak-pain was the maximal single-day
pain intensity. At the end of treatment, both the overall-pain and peak-pain decreased in the Four-Agents-Decoction (Si Wu
Tang) group and increased in the placebo group; however, the differences between the two groups were not statistically
significant. The trends persisted to follow-up phase. Statistically significant differences in both peak-pain and overall-pain
appeared in the first follow-up cycle, at which the reduced peak-pain in the Four-Agents-Decoction (Si Wu Tang) group did not
differ significantly by treatment length. However, the reduced peak-pain did differ profoundly among women treated for four
menstrual cycles (2.69 (2.06) cm, mean (standard deviation), for the 20 women with Four-Agents-Decoction and 4.68 (3.16) for
the 22 women with placebo, p=.020.) There was no difference in adverse symptoms between the Four-Agents-Decoction (Si
Wu Tang) and placebo groups. Conclusion/significance. Four-Agents-Decoction (Si Wu Tang) therapy in this pilot post-
market clinical trial, while meeting the standards of conventional medicine, showed no statistically significant difference in
reducing menstrual pain intensity of primary dysmenorrhoea at the end of treatment. Its use, with our dosage regimen and
treatment length, was not associated with adverse reactions. The finding of statistically significant pain-reducing effect in the
first follow-up cycle was unexpected and warrants further study. A larger similar trial among primary dysmenorrheic young
women with longer treatment phase and multiple batched study products can determine the definitive efficacy of this
historically documented formula. Trial Registration. Controlled-Trials.com ISRCTN23374750
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INTRODUCTION
Finding effective traditional Chinese herbal medicines has now
become one of the interests of medicine, pharmacology, and
agricultural biotechnology worldwide. The thousand-year-old
Chinese herbal medicine, mysterious to many, is usually composed
of 3–5 herbs in a formula or prescription for treatment of illness,
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the fact of a long history of human use, a clinical trial for
establishing evidence-based medicine has been thought essential.
Some clinical trials provide evidence for the effectiveness of
traditional Chinese medicine [1,2], but at present, consistent and
systematic evidence-based data are still lacking to support the
efficacy or safety and to separate the effects of the active
ingredients from those of their presumed complex compositions.
The decision to test Four-Agents-Decoction (Si Wu Tang)
resulted from the responses of three surveys of employees in
a research institute and women in a college for two consecutive
years, each consisting of an open-end questionnaire, administered
between 2000 and 2002 (unpublished data) on the prevalence of
using traditional Chinese medicine. Among the 227 research
institute employees who responded to the survey, Four-Agents-
Decoction ranked first as the most frequently used Chinese
medicine in the past year, and over half of the dysmenorrheic
college students had taken this formula for prophylaxis or relief of
menstrual discomfort.
Four-Agents-Decoction (Si Wu Tang) is originally listed in the
Prescriptions of People’s Welfare Pharmacy (in Chinese) as
a remedy for nourishing the blood and has been used as a basic
formula in traditional Chinese medicine for treating women’s
illnesses since the Sung Dynasty (12th century). The formula is
composed of dry roots of four plants native to Mainland China:
prepared Radix Rehmanniae praeparata (Soe Dee Huang), Radix
Paeoniae Alba (Bai Sau), Radix Angelicae Sinensis (Dang Guay), and
Rhizoma Ligustici Chuanxiong (Tsuan Chyong), which can be
obtained at Chinese medicine shops without seeking consultation
from traditional Chinese medicine practitioners. Traditionally, this
formula is used as a concoction.
This formula is worth studying, as non-specified dysmenorrhoea
is one of the most common gynaecological complaints in young
women. The prevalence rate for dysmenorrhoea varies worldwide;
estimates were from 44% in China [3], 51% in Singapore [4], 52–
64% in Mexico [5], 60–80% in the United States [6–8], 73% in
Sweden [9], 80% in Western Australia [10], to 45–95% in Britain
[11]. An estimated 42–51% of dysmenorrheic women reported
missing either school or work due to severe menstrual pain [8–9].
There is a subset of women who do not respond to conventional
treatment and turn to alternative medicine or therapy [12]. But
information on the use of alternative treatments is not clearly
known. In spite of several effective therapies, such as analgesics
and oral contraceptives [13–15], the morbidity from dysmenor-
rhoea remains a challenge to public health worldwide.
In traditional Chinese medicine dysmenorrhoea is termed as
‘‘painful menstruation,’’ and is not sub-classified as primary
dysmenorrhoea or secondary dysmenorrhoea. Menstrual pain is
the major symptom of primary dysmenorrhoea. In this study we
aimed for young women with primary dysmenorrhoea, who were
differentiated from secondary dysmenorrhoea by noninvasive
pelvic ultrasonography and with normal serum level of CA-125
at 35 U/ml as reference [16].
We did not find any published reports or warnings on the use of
Four-Agents-Decoction (Si Wu Tang). A post-market clinical trial
(phase IV) was thus applied to examine effectiveness by the
improvement of primary dysmenorrhoea and assess adverse
reactions by the routine clinical examination in conventional
medicine and the symptoms in traditional Chinese medicine.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Participants
Ethical approval for this study was obtained from the Human
Ethics Committee of National Health Research Institutes, Taiwan.
We recruited and selected our participants at the Study Centre
through the following procedures: (a) recruitment: from January to
March of 2003, 453 young dysmenorrheic women who informed
us their interests in our poster or flyer distributed in colleges over
the Taipei Metropolitan area, and of those, 326 returned our
questionnaire regarding their history of health, menstruation
pattern, pain intensity, and the experience with Four-Agents-
Decoction (Si Wu Tang); (b) eligibility screen: 215 respondents aged
18 years or older were screened if they had cycles lasting 21–
35 days with the actual menses periods lasting three to seven days,
and they experienced at least 4 consecutive painful periods in the
past six months with the pain starting one day before or on the day
of onset of bleeding. Moreover, the women were not taking oral
contraceptive pills and agreed to refrain from sexual activity
during the study due to any confounding effect on pain and early
withdrawal by pregnancy, and they had no severe gastrointestinal,
gynaecological or autoimmune diseases, or gynaecological surgery,
including pregnancy; (c) consent to participate: 120 respondents
provided written, informed consent, which included agreeing to
take nothing but analgesics and study product provided by the
centre for the pain, to have examinations by both two
gynaecologists and four traditional Chinese medicine physicians,
to have blood drawn, and to have remaining blood specimens
stored after the tests, and to observe menstruation; (d) washout:
established baseline with provided analgesics (ibuprofen 400mg,
four times daily for three days) for pain relief for 2–4 menstrual
cycles; (e) confirmation: 95 primary dysmenorrheic women were
confirmed after ruling out an organic lesion with a pelvic
ultrasound examination on the abdomen by both study gynaecol-
ogists and serum CA-125 level less than 35 U/ml or decreased to
40 U/ml from the second blood draw; and (f) final eligibility:8 1
women were eligible after excluding those with abnormal
hematological and biochemical indices of hepatic or renal
function; (g) enrollment: 78 young women were enrolled after three
women subsequently stopped participation during the baseline
period due to getting married, no longer having painful
menstruation, or not being willing to take study capsules
(Figure 1).
Interventions
We purchased the study products from a manufacturer with Good
Manufacturing Practice. This custom-made Four-Agents-Decoc-
tion (Si Wu Tang) was encapsulated with granules from
concentrated decoction made by water extraction in 1:13 ratio
from single batched roots of the four plants in equal proportions:
prepared Radix Rehmanniae praeparata (Soe Dee Huang), Radix
Paeoniae alba (Bai Sau), Radix Angelicae sinensis (Dang Guay), and
Rhizoma Ligustici chuanxiong (Tsuan Chyong), as prepared accord-
ing to the original pharmacopoeia. The plant origins in China
were known to the buyer of the pharmaceutical company.
According to the habitual usage of this formula and the
comparisons of the decoction made from raw materials with the
commercially available granules of concentrated decoction, the
concentrations of two quality control indicators-paeoniflorin and
ferulic acid-within the ranges requested by the Principal In-
vestigator were met. Provided by the pharmaceutical company,
the final product was free of E. coli and Salmonella and the levels of
heavy metals were 0.45 ppm for lead, 0.14 ppm for arsenic,
0.01 ppm for cadmium, and 0.02 ppm for mercury, all within
regulated limits (20, 5, 0.5, and 0.5 ppm, respectively). Every
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a capsule supply company to ensure concealment of the aroma
from the materials (Figure S1). The identical looking placebo
capsules were filled with a powder mixture of cornstarch and
caramel. Each capsule weighed approximately 500 mg.
Regimens of five capsules were packaged in aluminum packets
for easier handling and to prevent Four-Agents-Decoction (Si Wu
Tang) from moisture exposure. Clinic visit number and case
number were marked on each packet in both text and bar code.
The bar code with the number of unused capsules from used
packets was scanned into the database after each treatment cycle.
We determined the dosage of 15 capsules daily for five days
from the onset of bleeding or pain after taking considerations: (a)
habitual usages provided from the three surveys, (b) literature
reports, (c) a comparison of the concentrations of two indices,
paeoniflorin and ferulic acid, in a one-day dose of a commercially
available powder with the decoction made from raw materials, (d)
information from the study’s traditional Chinese medicine
physicians, and (e) input from the study’s leading gynaecologist.
For easier intake, we instructed the women to take the capsules
with warm water three times. A treatment cycle entailed a total of
75 capsules. The exact number of capsules taken each day was
recorded in the online diary, and any unfinished capsules were
brought back to the study nurse at the next clinic visit.
Participants’ mean menstrual cycle length at baseline was 27
and ranged from 21 to 43 days. However, some women’s cycles
had shortened after participating in the trial. We initially set the
treatment duration for three menstrual cycles [12]. In order to
have the post-treatment examination by the same six study
physicians, the treatment duration was imperatively extended to
four menstrual cycles for women having shortened cycles and for
those out of town for month-long winter break. We received
informed consent for additional treatment cycle from these
women. All women then were followed for three cycles after
completing treatment.
Objectives
We hypothesized that Four-Agents-Decoction (Si Wu Tang) had
a beneficial effect to treat primary dysmenorrhoea. Using
a scientific, not market-driven approach applying Good Clinical
Practice guidelines established by the Department of Health,
Taiwan (Publication No. 85067127), the objective of this pilot
study was to gather preliminary data on compliance, feasibility,
safety, and effectiveness to power a similar future trial.
Figure 1. Flow of participants through the enrollment and treatment.
doi:10.1371/journal.pone.0000719.g001
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(1) Primary outcome: visual analogue pain scale (VAS) We
collected the primary outcome data during the first five days
of each menstrual cycle using a horizontal unmarked visual
analogue scale (VAS) of 0–10 cm (0 cm representing no pain;
10 cm, severe pain) [17] with a sliding bar on the scale posted on
our Web site for participants to gauge their pain feeling. The
online scale matched 1000 scales in our database in order to
capture the maximal pain and detect small differences. The
participants recorded the pain intensity they experienced right
before taking ibuprofen (400 mg), which was provided by the
Study Centre for unbearable menstrual pain after holding it
off.
(2) Other pain measures In order to compare with the
results from other studies assessing the pain by verbal scale, we also
collected data on a 4-point pain scale (no pain, mild pain,
moderate pain, and severe pain) from the online questionnaire at
each cycle. Dichotomous responses (no pain or pain) were then
grouped from this scale.
(3) Confounders Data regarding the type and frequency of
the intake of all drugs and the use of other remedies, as possible
confounders, were collected along with the VAS pain intensity in
the electronic diary.
(4) Adverse reactions or events At the time of the pre-
treatment ultrasound screening and the post-treatment (end of
treatment) examination, a total of 20 ml of venous blood was
obtained for safety evaluation. Creatinine, BUN (urea nitrogen),
and uric acid were assessed for renal function; AST (aspartate
aminotransferase) and ALT (alanine aminotransferase), for
liver function; iron, TIBC (total iron binding capacity),
hemoglobin, and hematocrit, for anemic condition; and
mercury, arsenic, lead, cadmium, and copper, for heavy metal
toxicity.
Possible adverse reactions noted by traditional Chinese
medicine physicians were collected: inner heat reaction, (referring
to fire energy or Huo Chi in Pinyin, a symptom used in traditional
Chinese medicine, which corresponds to inflammation in Western
conventional medicine), such as blisters and pimples, and
disturbed menstruation, such as amenorrhea and menorrhagia.
Participants evaluated the latter symptom using a balance and
pads of three sizes supplied by the Study Centre and reported the
weight of soiled pads by size in the electronic diary. In addition,
any other discomforts or illnesses and the number of days missing
work or school were collected.
Sample size
We positioned this trial as a pilot study. Very few studies of non-
conventional treatment for primary dysmenorrhoea contain data
that can be referred for sample size calculation. We found 40
participants in one comparable study [18], and 100 participants in
another [19]. Clinical trials on conventional analgesics were thus
referred, in which the average pain reduction rate was 70% in the
treatment group and 30% in the placebo group. With 90% power
and 5% type I error (two-sided), we required 28 participants for
each arm of this trial. Therefore, 100 participants were to be
enrolled to allow for a 25% dropout rate.
Randomization—Sequence generation
The 78 dysmenorrheic women were first stratified by their past
experience or belief in the effectiveness of Four-Agents-Decoction
as reported in the recruitment questionnaire [20]. In each stratum
random codes with a permuted block randomization scheme were
generated by computer.
Randomization—Allocation concealment
The participants were not given their group assignment code. The
study physicians did not share their own examination results, did
not know the identity of the participants, did not handle the study
products, and did not know the assigned treatment. Two sets of 78
sealed opaque envelopes containing each individual’s treatment
assignment were prepared; one set was for the leading gynaecol-
ogist to keep for emergency care and the other was kept with
Principal Investigator. The two envelopes remained sealed until
data analysis.
Randomization—Implementation
All clinic visits for the 78 participants were arranged at the Study
Centre; the participants were randomized into Four-Agents-
Decoction or placebo groups based on the order of their chosen
date and the arrival time for their post-screening clinic. A total of
39 women were allocated to each treatment and placebo group,
according to the computer generated allocation sequence by study
statistician.
Blinding
The appearances of the study product and placebo capsules were
identical and no aroma was detected from either. Achievement of
blindness was validated before the trial in a group of 39 volunteers
(unpublished data). At the completion of treatment, we conducted
a simple survey asking the participants to guess whether they were
in the study product or placebo group in order to evaluate the
extent of study blindness.
Statistical methods
All data were stratified by treatment group and examined
separately. Study outcome was visual analog pain intensity given
as mean score (cm) and 95% confidence interval. Peak-pain was
the maximal single-day pain intensity and overall-pain was the
average pain intensity among days in pain. Data of the cycle
adjacent to the first treatment cycle was set as baseline. As
menstrual pain on the most intense day is considered unbearable
for many dysmenorrheic women, we focused our analysis on the
peak-pain.
Our outcome data were repeated measurements and correlated
across successive cycle points over the entire trial. The model fit by
generalized estimating equations (GEE) [21–22] is able to account
for longitudinal and correlated response data [23]. We tested the
nonlinear relationship and possible interaction effects between
treatments and cycles from baseline to the end of treatment with
the data based on individual trajectories of peak-pain measure-
ments. The GENMOD procedure in SAS (version 8.2 SAS
institute, Inc., Cary, North Carolina, U.S.A.) was used for the
modeling. The values for the variable ‘‘cycle’’ were set from 0 to 4
cycles according to the order of treatment cycle from baseline,
respectively, and the indicator variable ‘‘treatment’’ was used to
distinguish the two groups, with the placebo group as the
reference. The explanatory variables in the models consisted of
the indicator variables ‘‘treatment’’, ‘‘cycle’’, and the quadratic term
‘‘cycle
2’’ for nonlinear trends, as well as their interaction terms
‘‘cycle6treatment’’ and ‘‘cycle
26treatment’’. The treatment effect was
characterized using the two interaction terms.
We compared the peak-pain intensity by t-test for at each
treatment and follow-up cycle between the two treatment groups
and for those with three or four treatment cycles. Statistical
significance was determined at p#.05. Over-all pain intensity
distribution throughout the trial was presented and the same
comparisons were performed between the two treatment groups.
Trial of Chinese Herb Medicine
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Participant flow
Figure 1 summarizes the enrollment, treatment allocation, and
data analysis for the 78 participants with primary dysmenorrhoea.
Two women were withdrawn because they opened the capsules for
easier intake: one was from the Four-Agents-Decoction (FAD)
group at treatment cycle 1, and the other was from the placebo
group at treatment cycle 2.
Recruitment
Table 1 shows the time periods of recruitment, washout, baseline,
treatment, and follow-up phases. The trial took a total of eighteen
and a half months from January 2, 2003 to July 16, 2004.
Baseline data
The women in the two groups were comparable in age, college
education, weight, body-mass index, menstruation duration, and
cycle length (Table 2). Experience with the product in the two
groups was similar and no further adjustment was to be made in
the outcome analysis.
During wash-out and baseline phases the reported symptoms
episodes of symptoms-inner heat reaction, abnormal menses,
PMS-like symptoms, respiratory disorder or illness, and gastroin-
testinal disorder were few but slightly higher in the 39 participants
in the FAD group for a total of 147 cycles than in the 39
participants in the placebo group for a total of 152 cycles (Table 3).
Numbers analyzed
Two women failed to comply with the treatment, resulting in
97.4% compliance rate. The numbers of participants at baseline
and the treatment phase from cycle 1 to 4 were 39 and 38, 38, 38,
20 for the Four-Agents-Decoction (Si Wu Tang) group and 39 and
39, 38, 38, 22 for the placebo group.
Outcomes and estimation
Visual analog pain intensity was our outcome. The GEE model
(Figure 2) fitted with the explanatory variables, treatment and cycle,b y
the approach with ‘‘unstructured working correlation’’ [21], shows
trends of peak-pain decreasing in the FAD group and increasing in
the placebo group. Regression parameter estimates along with the
robust estimates of standard errors and test significance are
detailed in the table following the graph. The model indicates
a highly significant treatment effect, which was explained by the
interaction terms- cycle*treatment (p=.010) and cycle
2*treatment
(p=.0136)- after the difference in the peak-pain scores of the two
groups was adjusted for cycle trends.
These 78 women’s menstrual pain pattern throughout the trial
is shown in Figure 3 for their peak-pain intensity and in Figure 4
for the over-all pain intensity. The two distribution patterns were
similar. The mean and 95% CI of pain scores are shown along
with the line graphs. The pain of both groups diminished after
treatment cycle 1. However, at treatment cycle 2, the pain
increased in the active group, whereas the pain was the least in the
placebo group. At treatment cycle 3, the pain intensity was
decreased in the FAD group and increased in the placebo group;
the changes persisted to the treatment cycle 4 and follow-up cycle
1. With a rise at follow-up cycle 2 and 3, the pain scores of the
FAD group were still lower than those during the pre-treatment
phase. On the other hand, the scores of the placebo group
remained similar over the post-treatment phase. The two
treatment groups differed at treatment cycle 4 insignificantly; but
the difference reached statistical significance at follow-up cycle 1
(p=.029 for overall-pain and p=.036 for peak-pain).
Peak-pain intensity was further analysed. The mean reduced
peak-pain score at follow-up cycle 1 in the FAD group did not
differ significantly by treatment length (p=.125). Figure 5 shows
the reduced peak-pain did differ profoundly among women
treated for four menstrual cycles (2.69 (2.06) cm, mean (standard
deviation), for the 20 women with FAD and 4.68 (3.16) cm for the
22 women with placebo, p=.020.) The reduction was more than
2 cm in the FAD group, whereas less than 1 cm in the placebo
group. The GEE model also indicated a significant beneficial
treatment effect in these 42 women.
The consumption of ibuprofen and other analgesics was low
during the pre-treatment phase, as well as in the subsequent
treatment cycles. Of the women who ever took study-provided
ibuprofen during a menstrual period, the percentage of women
using one tablet decreased from baseline to treatment cycle 1–4,
43.6% to 31.6%, 28.9%, 21.1%, and 25.0% for the FAD group
and 23.1% to 15.4%, 21.1%, 21.1%, and 18.2% for the placebo
group. And using more than one tablet was 12.8%, 10.5%, 21.1%,
28.9%, and 10.0% for the FAD group, and 28.2%, 20.5%, 13.2%,
13.2%, and 18.2% for the placebo group, respectively. For the use
of other analgesics, including ibuprofens of other brands and
acetaminophens, the percentage was very low, 0%, 5.26%, 5.26%,
2.63%, and 0% for the FAD group and 0%, 5.13%, 0%, 2.63%,
and 2.63% for the placebo group. Twenty-four women in the FAD
group and 19 women in the placebo group in the pre-treatment
phase had ever used other analgesics or additional remedies,
including heating treatment, drinking hot liquids, eating choco-
lates or black sugar, or physical exercise, etc., the number of users
decreased in both groups during the treatment phase; 18 women
in the FAD group and 14 women in the placebo group.
Table 1. Time periods of trial progression.
......................................................................
Phase Activity Dates (m/d/year)
Recruitment Assessment for eligibility 01/02/03,5/26/03
Wash-out Informed consent collection Medical
screening visits
06/02/03,09/17/03
Baseline Pre-treatment clinic visits 11/20/03,12/18/03
Treatment Cycle 1–4 clinic visits 12/12/03,04/15/04
Follow-up Cycle 1–3 clinic visits Post-treatment
examination
03/18/04,07/16/04
doi:10.1371/journal.pone.0000719.t001
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Table 2. Pre-randomization characteristics of the 78 women
with primary dysmenorrhoea.
......................................................................
Characteristic
Four-Agents-
Decoction
(n=39)
Placebo
(n=39)
Age mean (SD*), years 23.6 (2.97) 23.3 (2.92)
College education, n (%) 39 (100) 39 (100)
Past user or believer, n (%) 39 (79) 39 (76)
Weight mean (SD), kg 51.7 (5.71) 52.0 (6.01)
Body-mass index mean (SD), kg/m
2 19.8 (2.27) 19.8 (1.75)
Menstruation duration mean (SD), days 5.66 (0.98) 5.77 (0.95)
Menstrual cycle length mean (SD), days 27.2 (2.76) 27.2 (3.52)
*SD, standard deviation
doi:10.1371/journal.pone.0000719.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Trial of Chinese Herb Medicine
PLoS ONE | www.plosone.org 5 August 2007 | Issue 8 | e719We did not obtain significant numbers of dichotomous
responses (pain or no pain) during or at the end of treatment
phase when the FAD and placebo groups were compared. The
percentage of women having no menstrual pain in the FAD group
was slightly higher during treatment cycle 1–4, 13.2%, 10.5%,
10.5%, and 15% compared with 2.6%, 7.9%, 5.3%, and 9.1% in
the placebo group, respectively (Table 4). The study was not
powered to assess the outcome of work or school absence; four
women from the FAD group and two from the placebo group took
absence from work or school during the treatment phase.
Ancillary analyses
At the end of treatment, 92% (35/38) of the FAD group and 53%
(20/38) of the placebo group correctly identified the content of
their capsules. Of the women who guessed correctly, 62.9% (22/
35) and 20% (4/20) in the respective groups had gastric reflux
(belch) during the course of treatment. Gastric reflux occurred
more often with FAD but had no association with the treatment
length of three or four cycles. Seventy-five percent (12/16) of
women with FAD and that guessed their group correctly when
surveyed at the end of 3-cycle treatment had gastric reflux,
compared to 33.3% (2/6) in the placebo group. The gastric reflux
occurred less in women who had four treatment cycles and guessed
their group correctly, 52.6% (10/19) women with FAD and 14.3%
(2/14) women with placebo. Only one woman in the FAD group
reported in the post-trial questionnaire that her reported pain
intensities were affected by the released aroma.
Pulsatility index of uterine arteries (PI) was used as a comple-
mentary tool to evaluate menstrual pain [24]. It is an averaged
value of the measurements taken by both gynaecologists in
alternate order on each participant during her menstruation at
ultrasound examinations for pelvic lesions. Both PI (pulsatility
index) of right and left uterine arteries decreased gradually from
day 1 to day 5 at both screening and post-treatment (Table S1), the
trend corresponded with the pattern of VAS pain scores.
Adverse events
Reactions associated with FAD noted by traditional Chinese
medicine physicians were inner heat reaction, such as blisters and
pimples, and disturbed menstruation, such as amenorrhea and
menorrhagia. The mean weight (standard deviation) of soiled pads
was not different between pre-treatment and treatment phases,
68.8 (37.2) and 70.4 (35.0) g for the FAD group, and 75.8 (44.3)
and 75.0 (49.3) g for the placebo group. The numbers of self-
reported symptom episodes after the treatment were still small, but
changed slightly. The most notable change was respiratory
disorder, which increased 10 episodes in the FAD group but none
in the placebo group. Both groups had a decreased episode of
PMS-like symptoms, 8 in the FAD and 7 in the placebo group.
The increase in the FAD group was only one episode for inner
heat reaction, abnormal menses, or gastrointestinal disorder or
illness (Table 3).
No levels of blood chemicals changed, except for an increase in
heavy metals at the end of treatment. This slight increase occurred
not only in the FAD group but also in the placebo group (Table 5).
DISCUSSION
Interpretation
Menstrual pain is the major symptom of primary dysmenorrhoea.
Both the overall-pain and peak-pain improved, after three cycles
of FAD treatment and persisted to the follow-up phase. At follow-
up cycle 1, the peak-pain score in the FAD group decreased
2.14 cm and 33.9%, meeting the minimum requirement of 1.3 cm
and 33%, respectively, for clinical significance with respect to
a change in pain severity [25–26]. As menstrual pain on the most
intense day is considered unbearable for many dysmenorrheic
women, this appears to be a delayed treatment benefit of FAD.
The methodology used to conduct a clinical trial of herbal
remedies is the foremost criterion before efficacy is assessed [27].
To the best of our knowledge, this study is the first trial of
a documented traditional Chinese herbal formula conducted as
rigorously as those for synthetic drugs. First, we randomised
a group of young women that were diagnosed concurrently by two
conventional Western physicians to differentiate primary from
secondary dysmenorrhoea.
Second, both conventional Western and traditional Chinese
medicine physicians participated together in the same trial to
observe possible adverse reactions or events from FAD. Our
observation of an increase in episodes of respiratory illness was
unexpected and might be due to chance, as the treatment phase
fell during the winter, when such illnesses increase greatly among
the general public. We do not rule out the need of scrutiny in
future trial. Adverse reactions or events historically attributed to
traditional Chinese medicine, such as inner heat reaction or
disturbed menstruation, did not increase in the FAD group
compared with the placebo group. There were no abnormalities of
hepatic or renal function, or heavy metal toxicity attributable to
the FAD as compared to placebo. Our regimen for this formula
appears safe.
Third, we masked the distinctive aroma of the FAD. Although
we validated our double-blind approach before recruitment, the
high rate of the women identifying the study product correctly
from unavoidable gastric reflux in the FAD group may be
attributed to the large dose or familiarity with this commonly used
Table 3. Self-reported episode frequency (person-episodes) of symptoms described in traditional Chinese medicine during the pre-
treatment (wash-out and baseline cycles) and treatment phases.
..................................................................................................................................................
Symptom Four-Agents-Decoction Placebo
Pre-treatment (n=39)
(147 cycles)
Treatment (n=38)
(134 cycles)
Pre-treatment (n=39)
(152 cycles)
Treatment (n=39)
(137 cycles)
Inner heat reaction 6715
Abnormal menses 5632
PMS-like 46 38 29 22
Respiratory disorder or illness 24 34 20 20
Gastrointestinal disorder or illness 11 12 12 8
doi:10.1371/journal.pone.0000719.t003
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PLoS ONE | www.plosone.org 6 August 2007 | Issue 8 | e719herb formula [28]. However, we took several approaches to allow
the best possible assessment for the pain. Specifically, (a) we
stratified the women by their experience with the formula before
the randomisation; (b) in order to control the quality of subjective
self-reported pain score data, we collected daily pain reports using
an unmarked VAS scale in diaries on our Web site, in an effort to
prevent them from making day by day comparison and changing
their instant subjective pain feeling; and (c) we compensated the
self-reported subjective measure by using PI from the pelvic
ultrasonography to serve as a complementary measure. The trend
of PI at the screening phase, while the PI and VAS pain score were
not affected by the treatment, is consistent with the reports that
a higher PI is related to more severe primary dysmenorrhoea [29–
30], and both PI and VAS pain score are the highest in the first
Figure 2. Peak-pain change based on the GEE model. Y-axis: Peak-Pain Score (cm) in the First Five Days of Menstruation. X-axis: Cycle (0 is the
baseline cycle closest to the start of treatment, 1–4 are treatment).
doi:10.1371/journal.pone.0000719.g002
Trial of Chinese Herb Medicine
PLoS ONE | www.plosone.org 7 August 2007 | Issue 8 | e719Figure 3. Distribution of peak-pain intensity throughout the trial. Y-axis: Peak-Pain Score (cm) in the First Five Days of Menstruation. X-axis: Cycles
within the phase. Phases of the entire trial.
doi:10.1371/journal.pone.0000719.g003
Figure 4. Distribution of overall-pain intensity throughout the trial. Y-axis: Overall-Pain Score (cm) in the First Five Days of Menstruation. X-axis:
Cycles within the phase. Phases of the entire trial.
doi:10.1371/journal.pone.0000719.g004
Trial of Chinese Herb Medicine
PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e719day of menstruation cycle [30]. Our self-reported VAS pain score
has been reliable for evaluating the effectiveness.
Despite the improvement on methodology for conducting
a rigorous clinical trial of traditional Chinese herbal medicine,
this study had limitations on recruitment, as very few sufferers can
be found at regular clinics. Although we received high response to
our recruitment questionnaire from the community, the low
participation-fewer than 50% (from 215 to 102 women) of the
initially screened respondents made their first hospital visit for the
trial information session and clinical evaluation-could be due in
part to the SARS outbreak. Owing to the time strain, we went on
with the 102 participants to be confirmed by the study
gynaecologists for primary dysmenorrhoea. Ninety-five primary
dysmenorrheic women passed the clinical screening and 78
women entered the treatment. The 78 treated participants
exceeded the minimum sample size of 56 but less than the
anticipated number of 100.
Operation of ad hoc study clinic visits by group may have
reduced the variability on the diagnosis by different physicians, the
drop-out rate, and the time to complete the entire trial, but
variations inherent in menstruation are unavoidable, which
require greater manpower to closely follow up the women in
order to meet the clinic schedules. Menstrual cycle length in the
FAD and the placebo groups was similar in both pre-randomi-
zation and treatment phases, but mean (standard deviation)
Figure 5. Peak-pain intensity distribution stratified by whether women had the 4th treatment cycle. Y-axis: Peak-Pain Score (cm) in the First Five
Days of Menstruation. X-axis: Cycles within the phase. Phases of the entire trial.
doi:10.1371/journal.pone.0000719.g005
Table 4. Percentage of women who did not feel pain after
receiving the treatment.
......................................................................
Treatment Four-Agents-Decoction % (n) Placebo % (n)
Cycle 1 13.2 (5/38) 2.6 (1/39)
Cycle 2 10.5 (4/38) 7.9 (3/38)
Cycle 3 10.5 (4/38) 5.3 (2/38)
Cycle 4 15.0 (3/20) 9.1 (2/22)
doi:10.1371/journal.pone.0000719.t004
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PLoS ONE | www.plosone.org 9 August 2007 | Issue 8 | e719changed from 27.2 (2.76) to 32.1 (5.08) days and from 27.2 (3.52)
to 31.4 (4.09) days, respectively, resulting in an extra cycle of
baseline for 31 women and an extension of treatment from three to
four cycles for 42 women.
Generalizability
Whether FAD has a clear curing effect for use in clinical medicine
to treat primary dysmenorrhoea needs to be elucidated by a larger
trial. It will require detailed sample size calculation covering
different geographical areas, age groups, and ethnic groups or
races for assessing generalisability. A longer treatment phase
should be incorporated for obtaining optimal dose and treatment
length. Multiple batches of the product can also be included for
determining the extent of the efficacy.
Overall evidence
We did not find the same distinct effect from FAD treatment
among 78 women as from synthetic analgesics or a significant
reduction of menstrual pain after a pre-determined three-month
(three cycles) study period of treatment [12]. But a larger clinical
trial with 260 participants may obtain significant pain improve-
ment by a formula composed of three Chinese herbs [31].
Starting from the treatment cycle 3, both the overall-pain and
the peak-pain intensity reduced in the FAD group and rose in the
placebo group. The changes from 4.82 at baseline to 3.30 cm at
follow-up cycle 1 for the FAD group and from 5.51 to 4.63 for the
placebo group are comparable to the study of vitamin E treatment
for dysmenorrhoea, in which the pain reduction was from 5.5 to
3.5 with vitamin E versus 5.4 to 4.3 with placebo after two months
of treatment [19]. The persistent pain reducing effect at treatment
cycle 4 and follow-up 1 indicates that a longer treatment and
follow-up is required in future trials so that the slow releasing
characteristic inherent in the theory of traditional Chinese
medicine can be accurately assessed.
To the best of our knowledge, no active ingredients in FAD
have been identified. In our post hoc preliminary study of the
mechanism of action of Four-Agents-Decoction for treating
primary dysmenorrhoea, cyclooxygenase-2 (COX-2) was inhibited
by 85% in 1% of the same solution that was used for assessing
quality control of the study product. Our series of studies from the
historical use, the surveys of usages, the post-market clinical trial,
to the biochemical mechanism provide the clinical plausibility for
FAD in relieving the worst menstrual pain intensity unrelated to
organic lesions.
SUPPORTING INFORMATION
Figure S1 Custom-made study product: Four-Agents-Decoction
(Si Wu Tang)
Found at: doi:10.1371/journal.pone.0000719.s001 (2.81 MB TIF)
Table S1 Distribution of pulsatility index and the corresponding
pain score on visual analog, presented as mean (standard
deviation).
Found at: doi:10.1371/journal.pone.0000719.s002 (0.03 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0000719.s003 (0.43 MB
PDF)
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0000719.s004 (0.11 MB
DOC)
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Biochemical Four-Agents-Decoction Placebo
Screening (n=38) Post-treatment (n=38) Screening (n=38) Post-treatment (n=38)
CA 125, U/mL 17.9 (7.42) 17.0 (9.85) 17.9 (6.63) 16.9 (9.08)
AST, IU/L 18.6 (4.06) 18.3 (3.31) 18.1 (3.76) 19.2 (4.62)
ALT, IU/L 13.2 (5.72) 13.7 (4.78) 12.3 (5.75) 12.4 (4.52)
Uric acid, mg/dL 4.40 (1.32) 4.17 (1.06) 4.40 (1.15) 4.28 (0.97)
Urea nitrogen, mg/dL 10.5 (2.29) 10.9 (2.85) 11.2 (2.31) 11.2 (2.87)
Creatinine, mg/dL 0.79 (0.11) 0.77 (0.08) 0.79 (0.09) 0.80 (0.08)
Lead, mg/L 1.82 (0.78) 2.47 (1.06) 1.39 (0.48) 2.61 (1.06)
Mercury, mg/L 2.29 (1.71) 3.94 (1.72) 3.06 (2.42) 3.71 (1.33)
Arsenic, mg/L 6.89 (3.11) 8.21 (2.94) 7.29 (4.75) 8.36 (3.86)
Copper, mg/L 955.3 (116.0) 994.7 (135.8) 990 (151.9) 1037 (149.7)
Cadmium, mg/L 0.99 (0.38) 1.03 (0.50) 0.94 (0.43) 0.96 (0.50)
Serum Iron, mg/dL 66.1 (37.2) 64.6 (32.8) 74.7 (31.5) 66.0 (30.4)
Hemoglobin, g/dL 12.6 (0.89) 12.4 (1.00) 12.6 (0.85) 12.6 (0.96)
Hematocrit, % 38.8 (2.32) 37.0 (2.42) 38.6 (2.08) 37.3 (2.34)
Regulated limits and actual levels of heavy metals in the study product-FAD: lead,20 ppm, 0.45 ppm; arsenic,5 ppm, 0.14 ppm; cadmium,0.5 ppm, 0.01 ppm;
mercury,0.5 ppm, 0.02 ppm.
doi:10.1371/journal.pone.0000719.t005
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